Navigation Links
Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab
Date:12/13/2012

Lilly will continue to develop additional treatment options for patients with autoimmune diseases."

The decision to stop the FLEX-M study is expected to result in a fourth-quarter charge in the range of $20 million to $35 million (pre-tax), or approximately $0.02 per share (after-tax). The company's previously issued financial guidance for 2012 remains unchanged.

About the FLEX-M Study

The FLEX-M study (study BCDM) is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tabalumab in patients with moderate-to-severe rheumatoid arthritis who had an inadequate response to methotrexate therapy. This pivotal registration study includes the assessment of the effect of tabalumab on structural progression.   

About BAFF and Tabalumab 

BAFF (B cell activating factor) is a cytokine that promotes B cell survival, proliferation and activation. In the presence of excess BAFF, B cells, including autoreactive B cells, are not appropriately eliminated by the immune system and may therefore contribute to the development of RA by producing autoantibodies and proinflammatory cytokines and "helping" autoreactive T cells. BAFF exists in both membrane-bound and soluble forms.

Tabalumab is a human immunoglobulin G subclass 4 (IgG4) monoclonal antibody (MAb) that inhibits both membrane-bound and soluble B cell activating factor (BAFF). Tabalumab is currently in Phase 3 development as a potential treatment for rheumatoid arthritis and systemic lupus erythematosus.

About Lilly's Autoimmune Pipeline

Tabalumab is one of three potential new medicines in late-stage clinical development for a variety of autoimmune conditions. The others are ixekizumab, an anti-IL-17 monoclonal antibody, for psoriasis and psoriatic arthritis, and baricitinib, a JAK1 and JAK2 inhibitor being developed in collaboration with Incyte Corporation, for RA, psoriasi
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lilly Provides Update on Next Steps for Solanezumab
2. Lilly to Expand Indianapolis Insulin Manufacturing Operations
3. Lilly Names Melissa Barnes Chief Ethics and Compliance Officer and Senior Vice President; Announces Retirement of Anne Nobles
4. Lilly Celebrates 18th Consecutive Year as One of Working Mothers 100 Best Companies
5. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
6. Lilly Announces Results From Lung Cancer Study
7. Lilly Announces Retirement of Robert Armitage, Names Michael Harrington Senior Vice President and General Counsel
8. Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
9. U.S. Court of Appeals Upholds Validity of Lillys Alimta Compound Patent
10. Lilly Revises 2012 Reported Guidance to Reflect Income from Early Payment of Amylin Obligations
11. Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)...  The recent flurry of PBM mergers and ... scrambling to identify a pharmacy benefit manager that ... retail pharmacy chain, or other potentially conflicting entity. ... Catamaran, Rite Aid,s $2 billion acquisition of EnvisionRx, ... $10 billion are just the latest examples of ...
(Date:5/28/2015)... May 28, 2015   Sanovas, Inc., a rapidly ... the Top 50 Start-Up Companies in the World at the Silicon ... Logo - http://photos.prnewswire.com/prnh/20150528/219097LOGO ... segment experts with direct domain experience screened 2,716 companies from ... Property, Business Model, and Team. This select list was further ...
(Date:5/28/2015)... 28, 2015  Array BioPharma Inc. (NASDAQ: ARRY ... (licensed to AstraZeneca) at the 2015 American Society of ... May 29 – June 2, 2015 in ... advancing in a total of 6 pivotal trials, with ... (binimetinib monotherapy in NRAS mutant melanoma patients) and SUMIT ...
Breaking Medicine Technology:Citizens Rx Addresses Recent PBM Consolidation and Rising Pharmacy Costs 2Citizens Rx Addresses Recent PBM Consolidation and Rising Pharmacy Costs 3Sanovas Awarded Global "Top-50" Start-Up Company 2Sanovas Awarded Global "Top-50" Start-Up Company 3Array BioPharma Announces Clinical Data Presentations At The 2015 ASCO Annual Meeting 2Array BioPharma Announces Clinical Data Presentations At The 2015 ASCO Annual Meeting 3
... /PRNewswire/ -- Asenapine -- an,investigational drug being developed ... Nobel, for bipolar I disorder and,schizophrenia -- was ... acute manic and mixed episodes associated with bipolar,I ... a study,presented at the American Psychiatric Association's 2007 ...
... Presented at 2007 APA Meeting -, COLLEGEVILLE, ... four new studies examining safety and efficacy ... studied as a potential treatment for adults,with ... at the,2007 American Psychiatric Association annual meeting ...
Cached Medicine Technology:Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 2Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 3Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 2New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 3New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 5New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 6New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 7New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 8
(Date:5/28/2015)... May 28, 2015 CompanionDx ... company, announces that it will present their integrated ... testing at the annual American Society of Clinical ... sequencing evaluates the DNA in a patient’s tumor ... analyzed for key changes or somatic mutations. Pharmacogenomics ...
(Date:5/28/2015)... Beverly Hills, CA (PRWEB) May 28, 2015 ... a novel interactive keratoconus web application to ... Keratoconus has expanded in the last few years. This ... Even eye doctors are not aware of the nuances ... the Khanna Vision Institute, realized that websites can be ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Sexual ... technology that advances sexual health and wellbeing in ... University of San Francisco (USF) will be the ... sexual assault recording and reporting system. , ... transparent, and confidential reporting experience for college sexual ...
(Date:5/28/2015)... DC (PRWEB) May 28, 2015 ... designing and implementing innovative models of care for ... to support alternative reimbursements and help operationalize contracting ... Optimity also unveils a bi-weekly series of seven ... developing Outcomes Based Contracting. Optimity is a strategy, ...
(Date:5/28/2015)... May 28, 2015 Cancer survivors who ... improvements in physical activity, fitness and quality of life, ... Yale Cancer Center and Jennifer Ligibel, MD, senior physician ... Dana Farber Cancer Institute. The findings will be presented ... (ASCO) Annual Meeting in Chicago. , ...
Breaking Medicine News(10 mins):Health News:CompanionDx® Launches Integrated Genomic Solution at ASCO Meeting 2Health News:Dr.Khanna Announced the Release of an Interactive Web Application for Keratoconus Treatment 2Health News:University of San Francisco Becomes First in the Nation to Adopt College Sexual Assault Reporting System 2Health News:University of San Francisco Becomes First in the Nation to Adopt College Sexual Assault Reporting System 3Health News:Optimity Advisors Now Offers Outcomes Based Contracting Services to Support Engagement Model For New Healthcare Innovative Models of Care 2Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 2Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 3Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 4
... , , , HARRISBURG, ... individuals have received free dental care, valued at nearly $160,000, ... dental insurer United Concordia Dental. , , ... commitment to provide free preventive services to those who cannot ...
... , MIAMI, July 23 Following a ... and a leader in sports nutrition for over 40 years, continues ... weekend Twinlab,s 2009 Mobile Beach Bash ... Miami, Florida. For those eager to show-off their six-pack abs for ...
... , SUNRISE, Fla., July 23 ... delivering intelligent devices and biologics that help monitor, diagnose and ... MARVEL-1 data for presentation at the Heart Failure Society of ... , Chris O,Connor, MD, Head ...
... has shown that risky driving habits are putting young ... of their perceptions about road safety. The study surveyed ... police. Young drivers involved in the study who said ... crash. Previous research has confirmed risky, ...
... Beauty Professionals Encouraged to Share Educational Materials ... , , WASHINGTON, July 23 ... service program created to help women cope with the appearance-related changes of ... Cosmetology Association (NCA) to generate awareness and increase program participation during its ...
... , , , SAN ... OREX ) today announced that it has priced an underwritten ... a price of $7.50 per share. Net proceeds, after estimated ... $70.9 million. Orexigen has granted the underwriter a 30-day option ...
Cached Medicine News:Health News:More than 1,000 Underinsured and Uninsured Individuals Receive Free Dental Care 2Health News:Twinlab's(R) Mobile Beach Bash Heats Up After a Successful Kick-Off of the 2009 RateYourAbs.com Contest 2Health News:Bioheart Announces Acceptance of Marvel-1 Data for Presentation at the Heart Failure Society of America (HFSA) Meeting 2Health News:Bioheart Announces Acceptance of Marvel-1 Data for Presentation at the Heart Failure Society of America (HFSA) Meeting 3Health News:Risky driving puts P-platers at high danger of crash 2Health News:Look Good...Feel Better Launches Salon Awareness Campaign During National Breast Cancer Awareness Month 2Health News:Look Good...Feel Better Launches Salon Awareness Campaign During National Breast Cancer Awareness Month 3Health News:Orexigen(R) Therapeutics Prices Public Offering of Common Stock 2
1.25 mm x 2.5 mm blade. 135 degrees back scratcher. Round handle....
6 mm wide tip. Gentle tapered blade. Designated most popular model or size....
9 mm wide tip. Designated most popular model or size....
4 mm wide tip....
Medicine Products: